Rum_Tequila
7 minutes ago
difficult to see how RDGL can fail risk / benefit analysis at this point, FDA granted them BDD, Vivos submitted a huge amount of material, in the original submission PR it even stated there was a high likelihood of followup to questions needed, FDA just didn’t have enough time (too much on their pla